Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
21.8M
-
Number of holders
-
27
-
Total shares
-
4.89M
-
Shares change
-
+3.21M
-
Total reported value, excl. options
-
$13.5M
-
Value change
-
+$5.62M
-
Number of buys
-
18
-
Number of sells
-
-7
-
Price
-
$2.77
Significant Holders of Rein Therapeutics, Inc. - Common Stock, par value $0.001 per share (RNTX) as of Q2 2024
filings reported holding RNTX - Rein Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2024.
Rein Therapeutics, Inc. - Common Stock, par value $0.001 per share (RNTX) has 27 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4.89M shares
of 21.8M outstanding shares and own 22.42% of the company stock.
Largest 10 shareholders include UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO (1.78M shares), Alyeska Investment Group, L.P. (540K shares), VANGUARD GROUP INC (506K shares), Nantahala Capital Management, LLC (464K shares), Cable Car Capital LLC (420K shares), Prosight Management, LP (265K shares), Senvest Management, LLC (231K shares), GEODE CAPITAL MANAGEMENT, LLC (170K shares), Sigma Planning Corp (126K shares), and Kepos Capital LP (106K shares).
This table shows the top 27 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.